Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synageva BioPharma SBC-102 Gets FDA ODD
SBC-102 is a protein designed to be identical to the enzyme that is missing. It is being evaluated in preclinical studies as a potential enzyme replacement therapy, or
SBC-102 is a protein designed to be identical to the enzyme that is missing. It is being evaluated in preclinical studies as a potential enzyme replacement therapy, or
Winston Pharma’s application is expected to be subject to a standard review with a Prescription Drug User Fee Act (PDUFA) date in the second half of 2011. Winston
AVI-4658 is an RNA-based therapeutic employing AVI’s new phosphorodiamidate morpholino oligomer (PMO) based chemistry and exon skipping technologies. It is being developed as a systemic treatment for patients
Esker said that organisations in the pharmaceutical and medical equipment industry receive thousands of sales orders daily from pharmacies, clinics, hospitals and doctors who use fax or postal
N8295 is the novel component of Dynavax’s Universal Flu vaccine candidate. N8295 is a fusion protein comprised of NP and M2e, two highly conserved influenza antigens covalently linked
Under the collaboration Evonik and Elevance are also expected to further develop the application of metathesis catalysts within Elevance’s business scope. Elevance manufactures oils, lubricants additives, antimicrobials and
NextPharma claimed that the new line can fill capsules, coated tablets, tablets into various forms and sizes of bottles. Currently, the line is set up to provide six
Three Rivers Pharma said that primary endpoint of increased sustained virological response (SVR) in the clinical trial leading to the expanded labeling, was achieved thereby demonstrating that Infergen
HMGB1 is a nuclear DNA-binding protein, which is elevated in the body following infection or trauma and may be an important factor when developing therapeutics to treat these
DX-88 (ecallantide) has been approved by the FDA and is marketed as Kalbitor (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years